Streetbeat News

Earnings

CYTK

Cytokinetics projects 2024 revenue between $3M-$5M, with operating expenses of $420M-$450M and net cash utilization of $390M-$420M. After raising $83M through ATM equity and considering available long-term debt from Royalty Pharma, the company estimates a two-year cash runway.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:49 pm

MTUS

Metallus reported that its Q1 shipments are expected to be slightly lower than those in Q4 2023. This indicates a potential short-term decrease in operational output or sales.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:48 pm

OVV

Ovintiv (NYSE:OVV) reported Q4 2023 adjusted EPS of $2.35, surpassing the $1.95 estimate, and sales of $3.17B, exceeding the $2.72B estimate. This represents a 158.24% increase in EPS and a slight 1.43% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:48 pm

INGN

Inogen has projected its Q1 2024 revenue to be between $73M and $74M, which is below the estimated $80.63M. This forecast suggests a potential downturn in the company's financial performance compared to expectations.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:47 pm

WMK

Weis Markets reported a decrease in both earnings per share (EPS) and sales for Q4, with EPS dropping to $0.76 from $1.07 year-over-year (YoY) and sales decreasing to $1.21 billion from $1.31 billion YoY.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:47 pm

MTUS

Metallus reported a Q4 2023 EPS of $0.03, a significant improvement from a loss of $(0.75) in the same quarter last year. Net sales also saw a substantial increase, rising to $328.1M from $245.4M YoY.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:47 pm

TKO

TKO has provided its financial targets for FY24, projecting revenues between $2.575 billion and $2.65 billion, which is below the estimated $2.79 billion. The company also aims for an Adjusted EBITDA of $1.150 billion to $1.170 billion and a Free Cash Flow Conversion in excess of 50%.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:46 pm

AMBA

Ambarella projects its Q1 revenue to be between $52M and $56M, compared to the estimated $53.59M by analysts.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:42 pm

CRDO

Credo Technology forecasts Q4 revenue to be in the range of $59M-$62M, slightly above the estimated $59.84M. The company anticipates GAAP gross margin between 63.2% and 65.2%, and non-GAAP gross margin between 64.0% and 66.0%.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:41 pm

IMAX

IMAX anticipates its gross box office for 2024 to be similar to the figures reported in 2023, indicating a stable performance outlook for the company.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:40 pm